All Stories

  1. Psychiatry Between Ethics and Activism: Rethinking Professional Authority and Scientific Integrity in Contemporary Mental Healthcare
  2. Autonomy Under Uncertainty: Are We Overestimating Decision-Making Capacity in Psychiatric End-of-Life Contexts?
  3. Beyond Consensus, Beyond Closure: Rethinking Relapse in Schizophrenia Through a Multidimensional Lens
  4. Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia
  5. Digital Adverse Events: Rethinking Psychopathology and Public Mental Health in the Era of Human–AI Interaction
  6. Reclaiming Pharmacovigilance: Bridging the Evidence–Practice Gap in Psychopharmacology
  7. Co-Created Digital Pretherapy Psychoeducation for Outpatients in Specialized Mental Health Care: Usability Evaluation and Patient Satisfaction Study
  8. A Study in VigiBase of Clozapine Fatal Outcomes in 7,874 Middle-Aged versus 4,380 Young Adults
  9. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase
  10. Psychiatry is not the science of unhappiness
  11. Insomnio: enfoque clínico y terapéutico
  12. Clozapine and Suicide in VigiBase
  13. Fatal Outcomes in Use of Clozapine
  14. The Crisis of Meaning in Aging and the Expansion of Medically Unjustified Euthanasia: A Psychiatric Imperative
  15. Letter to the Editor regarding: “Towards a name change of schizophrenia: positive and negative symptoms disorder (PND)”
  16. On dosing equity, scientific responsibility, and what remains unsaid
  17. Clozapine and Regulatory Inertia: Revisiting Evidence, Risks, and Reform
  18. Co-Created Digital Pretherapy Psychoeducation for Outpatients in Specialized Mental Health Care: Usability Evaluation and Patient Satisfaction Study (Preprint)
  19. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature
  20. Perceived Stress and Clinical Insomnia in Primary Care: Associations with Lifestyle and Medication Use
  21. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
  22. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
  23. The Sleep Expectation–Reality Gap: Exploring Discrepancies Between Perceived and Ideal Sleep Duration in Primary Care Patients
  24. Reflections on the Potential and Risks of AI for Scientific Article Writing after the AI Endorsement by Some Scientific Publishers: Focusing on Scopus AI
  25. Clozapine pharmacovigilance in Croatia: underreporting of specific adverse drug reactions and excellent reporting of suicide attempts
  26. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
  27. A case of recurrent priapism during prolonged clozapine administration
  28. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data
  29. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety
  30. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature
  31. Exploring the Relationship Between Psychological Constructs and Decision-Making Preferences in Psychiatric Outpatients
  32. Implications of psychological reactance for clinical practice in psychiatry including a systematic review.
  33. Investigating in VigiBase® over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia
  34. Psychoeducational group interventions for adults diagnosed with attention-deficit/ hyperactivity disorder: a scoping review of feasibility, acceptability, and outcome measures
  35. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK
  36. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database
  37. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance
  38. Will ChatGPT3 Substitute for us as Clozapine Experts?
  39. Guía internacional Para una dosificación más Segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la Proteína C Reactiva y los niveles de clozapina
  40. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance
  41. Psychiatric Patients’ Perceived Health Control and Reactance: Implications for Medication Adherence
  42. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
  43. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)
  44. Escaping the Long Shadow Cast by Agranulocytosis
  45. Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in VigiBase
  46. NURSING STUDENT’S VIEWS ON THE DUTY OF CARE: A CROSS-SECTIONAL STUDY IN TWO COUNTRIES
  47. Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review
  48. Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries
  49. Clozapine-induced myocarditis in Russia: Animal studies but no clinical studies
  50. Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase
  51. Psychometric Properties of the WHO-5 Well-Being Index among Nurses during the COVID-19 Pandemic: A Cross-Sectional Study in Three Countries
  52. Clozapine and the risk of haematological malignancies
  53. An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine
  54. Evaluating the Effect of a Telepsychiatry Educational Program on the Awareness, Knowledge, Attitude, and Skills of Telepsychiatry Among Spanish Psychiatrists during COVID-19 Pandemic
  55. An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s
  56. The duty to care and nurses' well-being during a pandemic
  57. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase
  58. Promoting safer clozapine dosing in the Americas
  59. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
  60. The Mediating Role of Resilience in the Relationship between Perceived Stress and Mental Health
  61. Miocarditis inducida por la clozapina: estudios animales pero no clínicos
  62. Clozapine-associated myocarditis in the World Health Organization’s pharmacovigilance database: Focus on reports from various countries
  63. Clinimetric Criteria for Patient-Reported Outcome Measures
  64. Exploring patterns in psychiatric outpatients’ preferences for involvement in decision-making: a latent class analysis approach
  65. Effect of necessity‐concern framework and polypharmacy on treatment adherence in psychiatric patients. Comparing an Argentinian with a Spanish sample
  66. An update on the complex relationship between clozapine and pneumonia
  67. Effects of a peer co-facilitated educational programme for parents of children with ADHD: a feasibility randomised controlled trial protocol
  68. Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics
  69. Patient-reported well-being: psychometric properties of the world health organization well-being index in specialised community mental health settings
  70. Assessment of shared decision-making in community mental health care: Validation of the CollaboRATE
  71. Psychometric properties of the Five‐item World Health Organization Well‐being Index used in mental health services: Protocol for a systematic review
  72. The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase
  73. A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology
  74. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics
  75. The necessity‐concern framework in the assessment of treatment adherence of psychiatric patients and the role of polypharmacy in a Spanish sample
  76. Data From the World Health Organization’s Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions
  77. Development and validation of the Patient’s Health Belief Questionnaire on Psychiatric Treatment
  78. Effectiveness and cost-effectiveness of a multicomponent intervention to improve medication adherence in people with depressive disorders - MAPDep: a study protocol for a cluster randomized controlled trial
  79. Ethnopsychopharmacology study of patients' beliefs regarding concerns about and necessity of taking psychiatric medications
  80. A Clinimetric Approach for Improving the Measurement of Pharmacophobia with Replication in Two Other Samples
  81. Meet Our Editorial Board Member
  82. Predictive validity of the Sidorkiewicz instrument in Spanish: Assessing individual drug adherence in psychiatric patients
  83. Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: a comparison among outpatient samples recruited in Spain, Argentina, and Venezuela
  84. The Art of Pharmacotherapy
  85. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach
  86. Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on Adherence
  87. Are Acceptance and Skepticism Determinant Factors for Adherence to Drug Treatment in Psychiatric Patients?
  88. Validity of the Control Preferences Scale in patients with emotional disorders
  89. Perceived Health Control
  90. Treatment-related decisional conflict in patients with depressive and anxious disorders
  91. The effect of a brief educational programme added to mental health treatment to improve patient activation: A randomized controlled trial in community mental health centres
  92. Preferencias por las decisiones compartidas en pacientes con depresión
  93. Métodos de valoración de la adherencia al tratamiento psiquiátrico en la práctica clínica
  94. Validation of the General Self-Efficacy Scale in psychiatric outpatient care
  95. Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence
  96. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting
  97. What Do Psychiatric Patients Believe Regarding Where Control Over Their Illness Lies?
  98. The relationship of psychological reactance, health locus of control and sense of self-efficacy with adherence to treatment in psychiatric outpatients with depression
  99. To what extent is treatment adherence of psychiatric patients influenced by their participation in shared decision making?
  100. Psychological reactance in psychiatric patients: Examining the dimensionality and correlates of the Hong Psychological Reactance Scale in a large clinical sample
  101. Psychiatric patients’ preferences and experiences in clinical decision-making: Examining concordance and correlates of patients’ preferences
  102. Validation of the Spanish version of the 9-item Shared Decision-Making Questionnaire
  103. Preferences for participation in shared decision making of psychiatric outpatients with affective disorders
  104. To what extent psychiatric patients feel involved in decision making about their mental health care? Relationships with socio-demographic, clinical, and psychological variables
  105. Risk factors for non-adherence to antidepressant treatment in patients with mood disorders
  106. Shared decision making in psychiatric practice and the primary care setting is unique, as measured using a 9-item Shared Decision Making Questionnaire (SDM-Q-9)
  107. Sociodemographic and clinical predictors of compliance with antidepressants for depressive disorders: systematic review of observational studies
  108. Psychiatric outpatients' self-reported adherence versus psychiatrists' impressions on adherence in affective disorders
  109. Estrategias de manejo de los antidepresivos desde la perspectiva de los pacientes: luchando interna y externamente
  110. Attitudes toward concordance in psychiatry: a comparative, cross-sectional study of psychiatric patients and mental health professionals
  111. Psychiatric patients’ attitudes towards concordance and shared decision making
  112. Mental health professionals' attitudes to partnership in medicine taking: a validation study of the Leeds Attitude to Concordance Scale II
  113. ¿Están relacionadas la obesidad y otras comorbilidades físicas con la enfermedad mental?
  114. Editorial [Hot Topic: Compliance, Adherence and Concordance in Medicine Taking of Psychiatric Patients (Guest Editor: Carlos De las Cuevas)]
  115. Towards a Clarification of Terminology in Medicine Taking Behavior: Compliance, Adherence and Concordance are Related Although Different Terms with Different Uses
  116. Adaptation and validation study of the Beliefs about Medicines Questionnaire in psychiatric outpatients in a community mental health setting
  117. Antidepressant Use in Early Pregnancy
  118. Lithium Use During Early, Late Pregnancy, and Breastfeeding
  119. Psychomotor performance and fitness to drive: The influence of psychiatric disease and its pharmacological treatment
  120. Versión española consensuada de la Severity of Dependence Scale (SDS)
  121. Fitness to Drive of Psychiatric Patients
  122. Attitudes toward psychiatric drug treatment: the experience of being treated
  123. Duloxetine-Induced Excessive Disturbing and Disabling Yawning
  124. Are psychotropics drugs used in pregnancy?
  125. Randomized Clinical Trial of Telepsychiatry through Videoconference versus Face-to-Face Conventional Psychiatric Treatment
  126. Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy
  127. Polypsychopharmacy
  128. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis
  129. Telepsychiatry: Psychiatric consultation through videoconference patients' perception and satisfaction
  130. Telepsychiatry: Psychiatric consultation through videoconference clinical results
  131. Polypharmacy in psychiatric practice in the Canary Islands
  132. Do therapeutic indications of antidepressants change from one year to another?
  133. Telepsychiatry in the Canary Islands: user acceptance and satisfaction
  134. Telepsiquiatría: utopía o realidad asistencial
  135. Benzodiazepines: more "behavioural" addiction than dependence
  136. Burnout en los profesionales de la atención a las drogodependencias
  137. Telepsiquiatría: utopía o realidad asistencial
  138. Variations in antidepressant prescribing practice: clinical need or market influences?
  139. The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study
  140. Benzodiazepine prescription is different in the public and private sectors
  141. Prescribed daily doses and ‘risk factors’ associated with the use of benzodiazepines in primary care
  142. Benzodiazepine audit in primary care
  143. PSYCHOPATHOLOGICAL PROFILE IN ANXIETY DISORDERS
  144. INSOMNIA AND AFFECTIVE DISORDERS